JP2008541759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008541759A5 JP2008541759A5 JP2008514767A JP2008514767A JP2008541759A5 JP 2008541759 A5 JP2008541759 A5 JP 2008541759A5 JP 2008514767 A JP2008514767 A JP 2008514767A JP 2008514767 A JP2008514767 A JP 2008514767A JP 2008541759 A5 JP2008541759 A5 JP 2008541759A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- composition
- subject
- treating
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 238000011319 anticancer therapy Methods 0.000 claims 4
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 239000013607 AAV vector Substances 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68627205P | 2005-05-31 | 2005-05-31 | |
| US60/686,272 | 2005-05-31 | ||
| PCT/US2006/020863 WO2006130580A2 (en) | 2005-05-31 | 2006-05-26 | Mutant il-10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012019756A Division JP2012130344A (ja) | 2005-05-31 | 2012-02-01 | 変異体ｉｌ−１０ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008541759A JP2008541759A (ja) | 2008-11-27 |
| JP2008541759A5 true JP2008541759A5 (enExample) | 2009-05-07 |
| JP4992025B2 JP4992025B2 (ja) | 2012-08-08 |
Family
ID=37482214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008514767A Active JP4992025B2 (ja) | 2005-05-31 | 2006-05-26 | 変異体ｉｌ−１０ |
| JP2012019756A Withdrawn JP2012130344A (ja) | 2005-05-31 | 2012-02-01 | 変異体ｉｌ−１０ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012019756A Withdrawn JP2012130344A (ja) | 2005-05-31 | 2012-02-01 | 変異体ｉｌ−１０ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7749490B2 (enExample) |
| EP (1) | EP1891103B1 (enExample) |
| JP (2) | JP4992025B2 (enExample) |
| AT (1) | ATE452908T1 (enExample) |
| CA (1) | CA2609543C (enExample) |
| DE (1) | DE602006011311D1 (enExample) |
| WO (1) | WO2006130580A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE516820T1 (de) | 2000-09-29 | 2011-08-15 | Schering Corp | Pegyliertes interleukin 10 |
| US7261882B2 (en) * | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| LT2816118T (lt) * | 2005-05-31 | 2018-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Genų pristatymo būdai |
| NO346530B1 (no) | 2006-09-28 | 2022-09-26 | Merck Sharp & Dohme | Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene. |
| CN102256625B (zh) | 2008-12-17 | 2013-11-20 | 默沙东公司 | 单和双peg il10的生产和用途 |
| JP6284482B2 (ja) | 2011-11-08 | 2018-02-28 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | インターロイキン４およびインターロイキンを含む融合タンパク質 |
| US20150044281A1 (en) * | 2012-01-06 | 2015-02-12 | The Regents Of The University Of Colorado, A Body Corporate | Methods for the treatment of multiple sclerosis and other demyelinating disorders |
| JP2016519108A (ja) * | 2013-04-18 | 2016-06-30 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−１０を疾病及び疾患の治療に用いる方法 |
| AU2014257123A1 (en) * | 2013-04-24 | 2015-10-15 | Armo Biosciences, Inc. | Interleukin-10 compositions and uses thereof |
| WO2014204816A2 (en) | 2013-06-17 | 2014-12-24 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| HRP20181913T1 (hr) * | 2013-07-18 | 2019-01-11 | Xalud Therapeutics, Inc. | Sastav za liječenje upale bolesti zglobova |
| CA2920679A1 (en) | 2013-08-30 | 2015-03-05 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN105848674A (zh) | 2013-11-11 | 2016-08-10 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| CA2963989A1 (en) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| CN107106655A (zh) | 2014-10-22 | 2017-08-29 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN107847583A (zh) | 2015-05-28 | 2018-03-27 | 阿尔莫生物科技股份有限公司 | 用于治疗癌症的聚乙二醇化白细胞介素‑10 |
| EP3341012B1 (en) | 2015-08-25 | 2025-07-30 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
| EP3445849B1 (en) * | 2016-04-22 | 2024-06-05 | Xalud Therapeutics, Inc. | Methods and compositions to enhance the anti-inflammatory effects of interleukin 10 |
| TW202033766A (zh) * | 2018-11-26 | 2020-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素１０變體及其衍生物 |
| WO2020163269A1 (en) * | 2019-02-04 | 2020-08-13 | Xenetic Biosciences, Inc. | Methods of using glycopolysialylated therapeutic proteins |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| EP3955955B1 (en) | 2019-04-19 | 2025-02-26 | Synerkine Pharma B.V. | A fusion protein comprising il13 |
| WO2021243057A1 (en) * | 2020-05-28 | 2021-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered interleukin-10 polypeptides and uses thereof |
| BR112023016873A2 (pt) * | 2021-03-12 | 2023-10-03 | Kolon Life Science Inc | Composição para prevenir ou tratar doenças cerebrais degenerativas |
| WO2023114958A1 (en) * | 2021-12-16 | 2023-06-22 | Xalud Therapeutics, Inc. | Dosing regimen for il-10 encoding expression construct |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6428985B1 (en) * | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| AU2001231532A1 (en) * | 2000-02-11 | 2001-08-20 | Maxygen Aps | Improved interleukin 10 |
-
2006
- 2006-05-26 DE DE602006011311T patent/DE602006011311D1/de active Active
- 2006-05-26 AT AT06771553T patent/ATE452908T1/de not_active IP Right Cessation
- 2006-05-26 JP JP2008514767A patent/JP4992025B2/ja active Active
- 2006-05-26 WO PCT/US2006/020863 patent/WO2006130580A2/en not_active Ceased
- 2006-05-26 EP EP06771553A patent/EP1891103B1/en active Active
- 2006-05-26 US US11/920,711 patent/US7749490B2/en active Active
- 2006-05-26 CA CA2609543A patent/CA2609543C/en active Active
-
2012
- 2012-02-01 JP JP2012019756A patent/JP2012130344A/ja not_active Withdrawn